Bone Marrow Transplantation - Table of Contents alert Volume 49 Issue 1

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 49, Issue 1 (January 2014) In this issue Review Commentary Original Articles Technical Report Letters To The Editor Also new AOP Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement The new Cancer Gene Therapy CGT has a new editor in chief with a new vision for the journal: Steven K. Libutti, M.D. - Director of Montefiore-Einstein Center for Cancer Care - Associate Director for Clinical Services, Albert Einstein Cancer Center.  Submit your research and be a part of the new Cancer Gene Therapy. You can follow CGT on Twitter @cgtnature     Review Top Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how? E Klyuchnikov, U Bacher, T Kroll, T C Shea, H M Lazarus, C Bredeson and T S Fenske Bone Marrow Transplant 2014 49: 1-7; advance online publication, May 27, 2013; 10.1038/bmt.2013.72 Abstract | Full Text Commentary Top Impact of palifermin on intestinal mucositis of HSCT recipients after BEAM A H E Herbers, W J F M van der Velden, A F J de Haan, J P Donnelly and N M A Blijlevens Bone Marrow Transplant 2014 49: 8-10; advance online publication, August 19, 2013; 10.1038/bmt.2013.118 Abstract | Full Text Original Articles Top CONDITIONING REGIMENS Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission G Kunter, J B Perkins, J Pidala, T Nishihori, M A Kharfan-Dabaja, T Field, H Fernandez, L Perez, F Locke, E Ayala, M Tomblyn, J L Ochoa-Bayona, B Betts, M Nieder and C Anasetti Bone Marrow Transplant 2014 49: 11-16; advance online publication, September 2, 2013; 10.1038/bmt.2013.121 Abstract | Full Text Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients A Bryant, I Nivison-Smith, E S Pillai, G Kennedy, A Kalff, D Ritchie, B George, M Hertzberg, S Patil, A Spencer, K Fay, P Cannell, L Berkahn, R Doocey, R Spearing and J Moore Bone Marrow Transplant 2014 49: 17-23; advance online publication, September 23, 2013; 10.1038/bmt.2013.142 Abstract | Full Text STEM CELL PROCUREMENT Impact of HLA mismatch direction on outcomes after umbilical cord blood transplantation for hematological malignant disorders: a retrospective Eurocord-EBMT analysis R Cunha, P Loiseau, A Ruggeri, G Sanz, G Michel, A PaolaIori, G Socié, W Arcese, A Picardi, C Dias de Heredia, B Rio, F Locatelli, T A O'Brien, I Yakoub-Agha, M Angel Diaz, N Milpied, H Bittencourt, M Pedro Souza, M Aljurf, D Charron, K Boudjedir, M Labopin, E Gluckman and V Rocha Bone Marrow Transplant 2014 49: 24-29; advance online publication, August 19, 2013; 10.1038/bmt.2013.120 Abstract | Full Text The impact of CD34+ cell dose on engraftment after SCTs: personalized estimates based on mathematical modeling T Stiehl, A D Ho and A Marciniak-Czochra Bone Marrow Transplant 2014 49: 30-37; advance online publication, September 23, 2013; 10.1038/bmt.2013.138 Abstract | Full Text PEDIATRIC TRANSPLANTS Risk factor analysis of idiopathic pneumonia syndrome after allogeneic hematopoietic SCT in children H Sano, R Kobayashi, A Iguchi, D Suzuki, K Kishimoto, K Yasuda and K Kobayashi Bone Marrow Transplant 2014 49: 38-41; advance online publication, August 19, 2013; 10.1038/bmt.2013.123 Abstract | Full Text ALLOGRAFTING Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation J C Marsh, R M Pearce, M B C Koh, Z Lim, A Pagliuca, G J Mufti, J Perry, J A Snowden, A J Vora, R T Wynn, N Russell, B Gibson, M Gilleece, D Milligan, P Veys, S Samarasinghe, M McMullin, K Kirkland and G Cook on behalf of the British Society for Blood and Marrow Transplantation (BSBMT) Clinical Trials Committee (CTCR 09-03) Bone Marrow Transplant 2014 49: 42-48; advance online publication, August 5, 2013; 10.1038/bmt.2013.115 Abstract | Full Text Uptake and use of recommendations for the diagnosis, severity scoring and management of chronic GVHD: an international survey of the EBMT–NCI Chronic GVHD Task Force R F Duarte, H Greinix, B Rabin, S A Mitchell, G Basak, D Wolff, J A Madrigal, S Z Pavletic and S J Lee Bone Marrow Transplant 2014 49: 49-54; advance online publication, August 19, 2013; 10.1038/bmt.2013.129 Abstract | Full Text The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT A Marek, M Stern, Y Chalandon, M Ansari, H Ozsahin, T Güngör, B Gerber, T Kühne, J R Passweg, A Gratwohl, A Tichelli, R Seger, U Schanz, J Halter and G Stussi on behalf of Swiss Blood Stem Cell Transplantation Bone Marrow Transplant 2014 49: 55-61; advance online publication, September 16, 2013; 10.1038/bmt.2013.132 Abstract | Full Text Risk factors for ICU admission and ICU survival after allogeneic hematopoietic SCT R Benz, U Schanz, M Maggiorini, J D Seebach and G Stussi Bone Marrow Transplant 2014 49: 62-65; advance online publication, September 23, 2013; 10.1038/bmt.2013.141 Abstract | Full Text Impact of being overweight on outcomes of hematopoietic SCT: a meta-analysis M Nakao, D Chihara, A Niimi, R Ueda, H Tanaka, Y Morishima and K Matsuo Bone Marrow Transplant 2014 49: 66-72; advance online publication, August 19, 2013; 10.1038/bmt.2013.128 Abstract | Full Text AUTOGRAFTING Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: A pilot study L G Lum, A Thakur, C Pray, N Kouttab, M Abedi, A Deol, W M Colaiace and R Rathore Bone Marrow Transplant 2014 49: 73-79; advance online publication, September 23, 2013; 10.1038/bmt.2013.133 Abstract | Full Text Reovirus as a successful ex vivo purging modality for multiple myeloma C M Thirukkumaran, Z Q Shi, J Luider, K Kopciuk, N Bahlis, P Neri, M Pho, D Stewart, A Mansoor and D G Morris Bone Marrow Transplant 2014 49: 80-86; advance online publication, August 26, 2013; 10.1038/bmt.2013.130 Abstract | Full Text MICROBIAL ISSUES Single-cell T-cell receptor-β analysis of HLA-A*2402-restricted CMV- pp65-specific cytotoxic T-cells in allogeneic hematopoietic SCT H Nakasone, Y Tanaka, R Yamazaki, K Terasako, M Sato, K Sakamoto, R Yamasaki, H Wada, Y Ishihara, K Kawamura, T Machishima, M Ashizawa, S-i Kimura, M Kikuchi, A Tanihara, J Kanda, S Kako, J Nishida and Y Kanda Bone Marrow Transplant 2014 49: 87-94; advance online publication, August 12, 2013; 10.1038/bmt.2013.122 Abstract | Full Text Predictors of invasive fungal infection in pediatric allogeneic hematopoietic SCT recipients J A Hol, T F W Wolfs, M B Bierings, C A Lindemans, A B J Versluys, A Wildt de, C E Gerhardt and J J Boelens Bone Marrow Transplant 2014 49: 95-101; advance online publication, October 14, 2013; 10.1038/bmt.2013.136 Abstract | Full Text POST-TRANSPLANT EVENTS Donor cell-derived leukemia after cord blood transplantation and a review of the literature: differences between cord blood and BM as the transplant source H Shiozaki, K Yoshinaga, T Kondo, Y Imai, M Shiseki, N Mori, M Teramura and T Motoji Bone Marrow Transplant 2014 49: 102-109; advance online publication, September 9, 2013; 10.1038/bmt.2013.127 Abstract | Full Text Expansion of donor-reactive host T cells in primary graft failure after allogeneic hematopoietic SCT following reduced-intensity conditioning M Koyama, D Hashimoto, K Nagafuji, T Eto, Y Ohno, K Aoyama, H Iwasaki, T Miyamoto, G R Hill, K Akashi and T Teshima Bone Marrow Transplant 2014 49: 110-115; advance online publication, September 9, 2013; 10.1038/bmt.2013.134 Abstract | Full Text GRAFT-VERSUS-HOST DISEASE Validation of the National Institutes of Health chronic GVHD Oral Mucosal Score using component-specific measures C W Bassim, H Fassil, J W Mays, D Edwards, K Baird, S M Steinberg, K M Williams, E W Cowen, S A Mitchell, K Cole, T Taylor, D Avila, D Zhang, D Pulanic, L Grkovic, D Fowler, R E Gress and S Z Pavletic Bone Marrow Transplant 2014 49: 116-121; advance online publication, September 2, 2013; 10.1038/bmt.2013.137 Abstract | Full Text Higher therapeutic CsA levels early post transplantation reduce risk of acute GVHD and improves survival J R Rogosheske, A D Fargen, T E DeFor, E Warlick, M Arora, B R Blazar, D J Weisdorf and C G Brunstein Bone Marrow Transplant 2014 49: 122-125; advance online publication, September 16, 2013; 10.1038/bmt.2013.139 Abstract | Full Text Effective prevention of GVHD using in vivo T-cell depletion with anti-lymphocyte globulin in HLA-identical or -mismatched sibling peripheral blood stem cell transplantation C Wolschke, T Zabelina, F Ayuk, H Alchalby, J Berger, E Klyuchnikov, U-M Pein, S Schumacher, G Amtsfeld, R Adjallé, F Wortmann, H Lellek, A Randenborgh, A Zander and N Kröger Bone Marrow Transplant 2014 49: 126-130; advance online publication, September 16, 2013; 10.1038/bmt.2013.143 Abstract | Full Text 18F-FDG PET/CT for the assessment of gastrointestinal GVHD: results of a pilot study C Bodet-Milin, M Lacombe, F Malard, E Lestang, X Cahu, P Chevallier, T Guillaume, J Delaunay, E Brissot, P Moreau, F Kraeber-Bodere and M Mohty Bone Marrow Transplant 2014 49: 131-137; advance online publication, September 30, 2013; 10.1038/bmt.2013.144 Abstract | Full Text Technical Report Top Depletion of naive T cells using clinical grade magnetic CD45RA beads: a new approach for GVHD prophylaxis D Teschner, E Distler, D Wehler, M Frey, D Marandiuc, K Langeveld, M Theobald, S Thomas and W Herr Bone Marrow Transplant 2014 49: 138-144; advance online publication, August 12, 2013; 10.1038/bmt.2013.114 Abstract | Full Text Letters To The Editor Top Early engraftment and full-donor chimerism after single-cord blood plus third-party donor dual transplantation in patients with high-risk acute leukemia I Sánchez-Ortega, M Arnan, B Patiño, M J Herrero, S Querol and R F Duarte Bone Marrow Transplant 2014 49: 145-147; advance online publication, August 12, 2013; 10.1038/bmt.2013.113 Full Text High-dose melphalan produces favorable response in a patient with multiple myeloma and coexisting essential thrombocythemia with JAK2 mutation T Nishihori, Y Hassoun, L Zhang, K Shain, M Alsina and M A Kharfan-Dabaja Bone Marrow Transplant 2014 49: 148-149; advance online publication, August 12, 2013; 10.1038/bmt.2013.117 Full Text EBV-driven relapse of peripheral T-cell lymphoma, masquerading as a post transplant lymphoproliferative disorder following allo-SCT C P Fox, M J Bishton, S O'Connor, S Hughes, J L Byrne and N Russell Bone Marrow Transplant 2014 49: 150-152; advance online publication, August 12, 2013; 10.1038/bmt.2013.125 Full Text Capnocytophaga canimorsus sepsis following BMT in a patient with AML: possible association with functional asplenia T Ugai, H Sugihara, Y Nishida, M Yamakura, M Takeuchi and K Matsue Bone Marrow Transplant 2014 49: 153-154; advance online publication, August 26, 2013; 10.1038/bmt.2013.126 Full Text Normal cognitive functioning in a patient with Hb Bart’s hydrops successfully cured by hematopoietic SCT B Pongtanakul, K Sanpakit, V Chongkolwatana and V Viprakasit Bone Marrow Transplant 2014 49: 155-156; advance online publication, August 26, 2013; 10.1038/bmt.2013.131 Full Text Plasticizer concentration in cord blood cryopreserved with DMSO R Yamaguchi, M Takanashi, M Ito, A Ogawa, M Hashimoto, Y Ishii, T Mazda, K Tadokoro, K Nakajima and M Minami Bone Marrow Transplant 2014 49: 157-158; advance online publication, September 9, 2013; 10.1038/bmt.2013.135 Full Text Hepatitis E virus infection in a hematopoietic stem cell donor C Koenecke, S Pischke, G Beutel, U Ritter, A Ganser, H Wedemeyer and M Eder Bone Marrow Transplant 2014 49: 159-160; advance online publication, September 23, 2013; 10.1038/bmt.2013.148 Full Text Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Bone Marrow Transplantation. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.